89 related articles for article (PubMed ID: 33199028)
21. The budget impact of cervical cancer screening using HPV primary screening.
Wright T; Huang J; Baker E; Garfield S; Hertz D; Cox JT
Am J Manag Care; 2016 Mar; 22(3):e95-105. PubMed ID: 26978241
[TBL] [Abstract][Full Text] [Related]
22. The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies.
Poljak M; Oštrbenk A
Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):43-7. PubMed ID: 23836358
[TBL] [Abstract][Full Text] [Related]
23. The health and economic effects of HPV DNA screening in The Netherlands.
Berkhof J; Coupé VM; Bogaards JA; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ
Int J Cancer; 2010 Nov; 127(9):2147-58. PubMed ID: 20112339
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
[TBL] [Abstract][Full Text] [Related]
25. Text messages to increase attendance to follow-up cervical cancer screening appointments among HPV-positive Tanzanian women (Connected2Care): study protocol for a randomised controlled trial.
Linde DS; Andersen MS; Mwaiselage JD; Manongi R; Kjaer SK; Rasch V
Trials; 2017 Nov; 18(1):555. PubMed ID: 29162148
[TBL] [Abstract][Full Text] [Related]
26. Options for triage and implications for colposcopists within European HPV-based cervical screening programmes.
Leeson S; Alalade R; Singh N; Nieminen P; Cruickshank M; Carcopino X; Bergeron C
Eur J Obstet Gynecol Reprod Biol; 2021 Mar; 258():332-342. PubMed ID: 33524777
[TBL] [Abstract][Full Text] [Related]
27. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans.
Maver PJ; Poljak M
Clin Microbiol Infect; 2020 May; 26(5):579-583. PubMed ID: 31539637
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of primary cytology and HPV DNA cervical screening.
Bistoletti P; Sennfält K; Dillner J
Int J Cancer; 2008 Jan; 122(2):372-6. PubMed ID: 17935124
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
Tang CH; Cheng WF; Jiang JH; You SL; Huang LW; Hsieh JY; Mukherjee P; Van Kriekinge G; Lee C
Asian Pac J Cancer Prev; 2019 May; 20(5):1377-1387. PubMed ID: 31127896
[TBL] [Abstract][Full Text] [Related]
30. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.
Tota J; Mahmud SM; Ferenczy A; Coutlée F; Franco EL
Sex Health; 2010 Sep; 7(3):376-82. PubMed ID: 20719230
[TBL] [Abstract][Full Text] [Related]
31. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic accuracy of high-risk HPV genotyping in women with high-grade cervical lesions: evidence for improving the cervical cancer screening strategy in China.
Xu H; Lin A; Shao X; Shi W; Zhang Y; Yan W
Oncotarget; 2016 Dec; 7(50):83775-83783. PubMed ID: 27626178
[TBL] [Abstract][Full Text] [Related]
33. Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage.
Campos NG; Castle PE; Wright TC; Kim JJ
Int J Cancer; 2015 Nov; 137(9):2208-19. PubMed ID: 25943074
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years.
Jin XW; Lipold L; Foucher J; Sikon A; Brainard J; Belinson J; Schramm S; Nottingham K; Hu B; Rothberg MB
J Gen Intern Med; 2016 Nov; 31(11):1338-1344. PubMed ID: 27418345
[TBL] [Abstract][Full Text] [Related]
35. Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening.
Huh WK; Williams E; Huang J; Bramley T; Poulios N
Appl Health Econ Health Policy; 2015 Feb; 13(1):95-107. PubMed ID: 25385310
[TBL] [Abstract][Full Text] [Related]
36. Pre-vaccination prevalence of infections with 25 non-high-risk human papillomavirus types among 1,000 Slovenian women in cervical cancer screening.
Učakar V; Poljak M; Oštrbenk A; Klavs I
J Med Virol; 2014 Oct; 86(10):1772-9. PubMed ID: 24978445
[TBL] [Abstract][Full Text] [Related]
37. Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
Oštrbenk A; Xu L; Arbyn M; Poljak M
J Clin Microbiol; 2018 Nov; 56(11):. PubMed ID: 30209184
[TBL] [Abstract][Full Text] [Related]
38. The value of improving failures within a cervical cancer screening program: an example from Norway.
Burger EA; Kim JJ
Int J Cancer; 2014 Oct; 135(8):1931-9. PubMed ID: 24615416
[TBL] [Abstract][Full Text] [Related]
39. Moving towards an organized cervical cancer screening: costs and impact.
Diaz M; Moriña D; Rodríguez-Salés V; Ibáñez R; Espinás JA; de Sanjosé S
Eur J Public Health; 2018 Dec; 28(6):1132-1138. PubMed ID: 29684144
[TBL] [Abstract][Full Text] [Related]
40. Provision of screening services for cervical and breast cancer - A scientific study commissioned by the European Board & College of Obstetrics and Gynaecology (EBCOG).
Vieira-Coimbra M; Nogueira-Martins N; Zadykowicz R; Rodrigues Gaspar H; Calleja-Agius J; Pakiz M; Mukhopadhyay S; Mahmood T
Eur J Obstet Gynecol Reprod Biol; 2023 Oct; 289():208-216. PubMed ID: 37679212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
